Additionally, Vγ2 TCR-targeting Y-body platform allowed for the simple replacement of the PD-L1 Fab to create a sequence of Vγ2 x TAAs, which enabled Vγ2Vδ2 T cells to target a broader spectrum of tumor types and helping a larger population of cancer patients. This evidence concerns the gene CD274 and neoplasm.